SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bal Pharma board to consider dividend

10 May 2016 Evaluate

Bal Pharma has informed that a meeting of the Board of Directors of the Company will be held on May 25, 2016, to take on record and approve the audited financial results of the Company for the financial year ended March 31, 2016; Appropriation of profits including recommendation of dividend, if any for the F.Y 2015-16; to consider various other A.G.M related aspects. As per the provisions of Bal Pharma Code of Conduct for prevention of insider trading, the trading window of the Company shall remain closed on all the specified persons of the Company, from May 13, 2016 and up to May 28, 2016.

The above information is a part of company’s filings submitted to BSE.

Bal Pharma Share Price

77.19 -1.28 (-1.63%)
21-Apr-2026 15:42 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.70
Dr. Reddys Lab 1220.00
Cipla 1232.60
Zydus Lifesciences 928.05
Lupin 2305.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×